M-M-R II Market Report 2026

M-M-R II Market Overview

• The M-M-R II market growth in the historic period has been driven by expansion of national immunization schedules, declining incidence of measles mumps and rubella • Market expansion is supported by increasing focus on outbreak prevention, rising investments in vaccine manufacturing capacity • Growth Driver: Rising Cases Of Measles, Mumps, And Rubella Driving The Market • Market Trend: Innovative Therapies And Regulatory Approvals In The M-M-R II Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under M-M-R II Market?

M-M-R II is a combination vaccine that protects against three viral infections (measles, mumps, and rubella). It contains live, attenuated (weakened) forms of these viruses. The vaccine stimulates the immune system to recognize and fight these viruses without causing the disease. M-M-R II is typically administered as a two-dose series, with the first dose given at 12 to 15 months of age and the second dose at 4 to 6, as part of routine childhood immunization programs. The main indication types of M-M-R II are measles, mumps, and rubella. Measles is a highly contagious viral infection characterized by fever, cough, runny nose, and a distinctive red, blotchy skin rash. The formulations are live attenuated vaccines and pre-filled syringes, and the distribution channels include hospitals, pediatric clinics, public health agencies, and retail pharmacies. It is used by various end users such as patients, infants, children, and adults.

What Is The M-M-R II Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on outbreak prevention, rising investments in vaccine manufacturing capacity, expansion of adult immunization programs, growing emphasis on global vaccination equity, increasing adoption of combination vaccine platforms. Major trends in the forecast period include increasing emphasis on routine childhood immunization programs, rising demand for combination vaccines, expansion of public immunization coverage, enhanced focus on vaccine safety and efficacy, growing use of pre-filled syringe formats.

Global M-M-R II Market Segmentation

1) By Indication: Measles, Mumps, Rubella 2) By Formulation: Live Attenuated Vaccine, Pre-Filled Syringes 3) By Distribution Channel: Hospitals, Pediatric Clinics, Public Health Agencies, Retail Pharmacies 4) By End User Patients: Infants, Children, Adults

What Are The Drivers Of The M-M-R II Market?

The rising cases of measles, mumps, and rubella disease are expected to propel the growth of the M-M-R II market going forward. Measles, mumps, and rubella are highly contagious viral diseases that can cause serious health complications, including fever, rash, swelling, and, in severe cases, neurological damage or congenital disabilities if rubella is contracted during pregnancy. The rising cases of measles, mumps, and rubella are attributed to lower vaccination rates, gaps in immunization coverage, and vaccine hesitancy among certain populations. The M-M-R II vaccine protects against measles, mumps, and rubella by stimulating the immune system to generate antibodies that defend against these viruses by lowering the risk of infection and serious health issues. For instance, in May 2024, according to the UK Health Security Agency, a UK-based government agency, in England, there were 51 laboratory-confirmed cases of mumps between January and March 2023, compared to 32 cases in the October to December 2022 period and 10 cases from July to September 2022. During the same period (January to March 2023), 31 laboratory-confirmed measles cases were reported, up from 7 cases in the previous quarter. Therefore, the rising cases of measles, mumps, and rubella disease are driving the M-M-R II industry. The increasing success rate of vaccination programs is expected to propel the growth of the M-M-R II market going forward. Vaccination programs refer to organized efforts by governments or health organizations to administer vaccines to individuals or groups to prevent the spread of infectious diseases. The success rate of vaccination programs is attributed to factors such as high public awareness, effective vaccine distribution systems, government support, and the availability of safe and efficacious vaccines. Vaccination programs play a crucial role in promoting the M-M-R II vaccine, which helps protect against measles, mumps, and rubella, lowering the occurrence of these diseases and enhancing public health. For instance, in June 2023, according to the UK Health Security Agency, a UK-based government agency, in the school-aged vaccination program, a total of 3,502,566 children (from Reception to Year 9) were vaccinated in 2022 to 2023, compared to 3,615,536 children in the same age range during 2021 to 2022. Therefore, the increasing success rate of vaccination programs is driving the M-M-R II industry.

Key Players In The Global M-M-R II Market

Major companies operating in the m-m-r ii market are Merck & Co. Inc.

Global M-M-R II Market Trends and Insights

The key trend in the M-M-R II market is developing innovative therapies such as live attenuated vaccines to enhance immunization efficacy and broaden protection against measles, mumps, and rubella. A live attenuated vaccine refers to a type of vaccine that contains a weakened form of the pathogen, which is still capable of inducing an immune response without causing disease. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for the intramuscular administration of the M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live). M-M-R II is a vaccine for preventing measles, mumps, and rubella in individuals 12 months and older. It is administered intramuscularly or subcutaneously, with the recommended primary vaccination at 12 to 15 months and a second dose at 4 to 6 years.

Regional Insights

North America was the largest region in the M-M-R II market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the M-M-R II Market?

The M-M-R II market consists of sales of single antigen vaccines, proquad vaccine, priorix vaccine, and ruvax vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the M-M-R II Market Report 2026?

The m-m-r ii market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the m-m-r ii industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.